ALK重排型肺癌的临床特征分析

Analysis of Clinical Features of ALK Rearrangement Lung Cancer

摘要: 目的：探讨ALK重排型肺癌的临床特征，为ALK阳性肺癌患者的个体化治疗提供依据。材料及方法：选取2016年11月至2019年3月期间我院收治的104例ALK重排阳性的肺癌患者作为阳性组，另随机选取172例ALK重排阴性的肺癌患者作为阴性组，回顾性分析ALK阳性患者的临床特征，数据采用SPSS 26.0软件进行统计分析。结果：ALK阳性组与ALK阴性组在年龄、吸烟史、病理类型、转移情况和TNM分期方面，差别具有统计学意义(P < 0.05)。ALK阳性组和EGFR阳性组患者在年龄、病理类型、转移情况以及TNM临床分期方面差异具有统计学意义(P均 < 0.05)。相较于野生型患者，ALK阳性患者以更年轻的不吸烟患者多见(P < 0.001)，两组患者均以女性、腺癌、周围型、易发生转移为主；ALK阳性组年轻、女性、不吸烟、腺癌、III~IV期肺癌患者比例高于野生组(P均 < 0.05)，两组在原发部位以及转移情况方面差异无统计学意义(P > 0.05)。结论：ALK阳性的NSCLC在年轻、不吸烟、腺癌、III~IV期临床分期患者比例较高；与EGFR突变相比，具有ALK基因重排的NSCLC的患者更年轻、更易表现为腺癌、临床分期晚、易发生转移；与野生型肺癌相比，ALK阳性的NSCLC多表现为年轻、女性、不吸烟、腺癌以及III~IV期临床分期。

Abstract: Objective: To explore the clinical characteristics of ALK rearranged lung cancer, and provide a basis for individualized treatment of ALK-positive lung cancer patients. Materials and Methods: 104 patients with ALK rearrangement-positive lung cancer admitted to our hospital from November 2016 to March 2019 were selected as the positive group, and 172 ALK-negative lung cancer patients were randomly selected as the negative group. The clinical characteristics of ALK-positive patients were analyzed retrospectively, and the data was statistically analyzed using SPSS 26.0 software. Results: The ALK-positive group and the ALK-negative group had statistically significant differences in age, smoking history, pathological type, metastasis and TNM staging (P < 0.05). The ALK-positive group and the EGFR-positive group had statistically significant differences in age, pathological type, metastasis, and TNM clinical stage (P < 0.05). Compared with wild-type patients, ALK-positive patients were more common in younger non-smokers (P < 0.001). The two groups of patients were mainly female, adenocarcinoma, peripheral type, and prone to metastasis; ALK-positive group was young and female. The proportion of patients with lung cancer, non-smokers, adenocarcinoma, and stage III~IV lung cancer was higher than that in the wild group (P < 0.05), and there was no significant difference in the primary site and metastasis between the two groups (P > 0.05). Conclusion: ALK-positive NSCLC has a higher proportion of young, non-smokers, adenocarcinoma, and clinical stage III~IV patients; compared with EGFR mutations, NSCLC patients with ALK gene rearrangement are younger and more likely to develop adenocarcinoma. Compared with wild-type lung cancer, ALK-positive NSCLC is mostly young, female, non-smoker, adenocarcinoma, and stage III~IV clinical stage.